Involvement of the endocannabinoid system in drug addiction

被引:432
作者
Maldonado, R [1 ]
Valverde, O [1 ]
Berrendero, F [1 ]
机构
[1] Univ Pompeu Fabra, Fac Ciencies Salut Vida, Neuropharmacol Lab, E-08003 Barcelona, Spain
关键词
D O I
10.1016/j.tins.2006.01.008
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Recent studies have shown that the endocannabinoid system is involved in the common neurobiological mechanism underlying drug addiction. This system participates in the primary rewarding effects of cannabinoids, nicotine, alcohol and opioids, through the release of endocannabinoids in the ventral tegmental area. Endocannabinoids are also involved in the motivation to seek drugs by a dopamine-independent mechanism, demonstrated for psychostimulants and opioids. The endocannabinoid system also participates in the common mechanisms underlying relapse to drug-seeking behaviour by mediating the motivational effects of drug-related environmental stimuli and drug reexposure. In agreement, clinical trials have suggested that the CB1 cannabinoid antagonist rimonabant can cause smoking cessation. Thus, CB1 cannabinoid antagonists could represent a new generation of compounds to treat drug addiction.
引用
收藏
页码:225 / 232
页数:8
相关论文
共 85 条
[1]   Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors [J].
Arnone, M ;
Maruani, J ;
Chaperon, F ;
Thiebot, MH ;
Poncelet, M ;
Soubrie, P ;
LeFur, G .
PSYCHOPHARMACOLOGY, 1997, 132 (01) :104-106
[2]   Δ9-tetrahydrocannabinol decreases somatic and motivational manifestations of nicotine withdrawal in mice [J].
Balerio, GN ;
Aso, E ;
Berrendero, F ;
Murtra, P ;
Maldonado, R .
EUROPEAN JOURNAL OF NEUROSCIENCE, 2004, 20 (10) :2737-2748
[3]   SR141716A reduces the reinforcing properties of heroin but not heroin-induced increases in nucleus accumbens dopamine in rats [J].
Caillé, S ;
Parsons, LH .
EUROPEAN JOURNAL OF NEUROSCIENCE, 2003, 18 (11) :3145-3149
[4]   Drug addiction [J].
Camí, J ;
Farré, M .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (10) :975-986
[5]   Lack of CB1 cannabinoid receptors modifies nicotine behavioural responses, but not nicotine abstinence [J].
Castañé, A ;
Valjent, E ;
Ledent, C ;
Parmentier, M ;
Maldonado, R ;
Valverde, O .
NEUROPHARMACOLOGY, 2002, 43 (05) :857-867
[6]   Involvement of central cannabinoid (CB1) receptors in the establishment of place conditioning in rats [J].
Chaperon, F ;
Soubrié, P ;
Puech, AJ ;
Thiébot, MH .
PSYCHOPHARMACOLOGY, 1998, 135 (04) :324-332
[7]   Endocannabinoid-mediated metaplasticity in the hippocampus [J].
Chevaleyre, V ;
Castillo, PE .
NEURON, 2004, 43 (06) :871-881
[8]   Cannabinoid CB1 receptor antagonism reduces conditioned reinstatement of ethanol-seeking behavior in rats [J].
Cippitelli, A ;
Bilbao, A ;
Hansson, AC ;
del Arco, I ;
Sommer, W ;
Heilig, M ;
Massi, M ;
Bermúdez-Silva, FJ ;
Navarro, M ;
Ciccocioppo, R ;
de Fonseca, FR .
EUROPEAN JOURNAL OF NEUROSCIENCE, 2005, 21 (08) :2243-2251
[9]   SR141716, a central cannabinoid (CB1) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats [J].
Cohen, C ;
Perrault, G ;
Voltz, C ;
Steinberg, R ;
Soubrié, P .
BEHAVIOURAL PHARMACOLOGY, 2002, 13 (5-6) :451-463
[10]   Nicotine-associated cues maintain nicotine-seeking behavior in rats several weeks after nicotine withdrawal:: Reversal by the cannabinoid (CB1) receptor antagonist, rimonabant (SR141716) [J].
Cohen, C ;
Perrault, G ;
Griebel, G ;
Soubrié, P .
NEUROPSYCHOPHARMACOLOGY, 2005, 30 (01) :145-155